- Home
- HASI vs SRRK Comparison
HASI vs SRRK Comparison
Compare HASI & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HASI | SRRK |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HASI | SRRK |
|---|---|---|
| Price | $32.74 | $44.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $39.88 | ★ $47.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | ★ 27.54 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $99,644,000.00 | N/A |
| Revenue This Year | $187.33 | N/A |
| Revenue Next Year | $16.20 | $20,271.77 |
| P/E Ratio | $14.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.98 | $22.71 |
| 52 Week High | $34.54 | $48.28 |
Technical Indicators
Market Signals| Indicator | HASI | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 62.46 |
| Support Level | $32.44 | $43.92 |
| Resistance Level | $33.38 | $48.28 |
| Average True Range (ATR) | 0.72 | 2.17 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 16.94 | 61.00 |
Price Performance
Historical ComparisonAbout HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.